Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.
暂无分享,去创建一个
[1] Henry P. Treffers,et al. Complement , 1966, The Yale Journal of Biology and Medicine.
[2] W E Wilkinson,et al. Alzheimer's disease: A study of epidemiological aspects , 1984, Annals of neurology.
[3] L M Schuman,et al. A case-control study of dementia of the Alzheimer type. , 1985, American journal of epidemiology.
[4] Joseph Rogers,et al. Immune system associated antigens expressed by cells of the human central nervous system , 1988, Neuroscience Letters.
[5] S. Styren,et al. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease , 1988, Neurobiology of Aging.
[6] D. Scott,et al. Rheumatold Arthritis and Senile Dementia of the Alzhelmer's Type , 1989 .
[7] P. Eikelenboom,et al. Complement activation in amyloid plaques in Alzheimer’s dementia , 1988, Virchows Archiv. B, Cell pathology including molecular pathology.
[8] D. Scott,et al. Rheumatoid arthritis and senile dementia of the Alzheimer's type. , 1989, British journal of rheumatology.
[9] P. Mcgeer,et al. Complement-activated oligodendroglia: A new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d , 1990, Neuroscience Letters.
[10] T. Koepsell,et al. A case‐control study of Alzheimer's disease , 1990, Annals of neurology.
[11] P. Mcgeer,et al. Anti-inflammatory drugs and Alzheimer disease , 1990, The Lancet.
[12] Anthony F Jorm,et al. A case‐control study of Alzheimer's disease in Australia , 1990, Neurology.
[13] V. ter meulen,et al. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[14] L. Kurland,et al. Rheumatoid arthritis and susceptibility to Alzheimer's disease , 1991, The Lancet.
[15] P. Mcgeer,et al. Prevalence of Dementia amongst Elderly Japanese with Leprosy: Apparent Effect of Chronic Drug Therapy , 1992 .
[16] P. Mcgeer,et al. Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Silverman,et al. A case‐control study of Alzheimer's disease in China , 1992, Neurology.
[18] A. Kaszniak,et al. Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.
[19] KennethRockwood,et al. The Canadian Study of Health and Aging* , 1994, Neurology.
[20] C. Cotman,et al. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. , 1994, Journal of immunology.
[21] W. McDonald,et al. Inverse association of anti‐inflammatory treatments and Alzheimer's disease , 1994, Neurology.
[22] P. Mcgeer,et al. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease , 1994, Brain Research.
[23] R. Myllykangas-Luosujärvi,et al. Alzheimer's disease and rheumatoid arthritis. , 1994, British journal of rheumatology.
[24] D. Birmingham,et al. Complement receptors and regulatory proteins: immune adherence revisited and abuse by microorganisms , 1994, Clinical and experimental immunology.
[25] M. Pericak-Vance,et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs , 1995, Neurobiology of Aging.
[26] M. Folstein,et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease , 1995, Neurology.
[27] D. Walker,et al. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains , 1995, Journal of neuroscience research.
[28] A. Hofman,et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? , 1995, Neurology.
[29] R. Mrak,et al. Correlation of Astrocytic S100β Expression with Dystrophic Neurites in Amyloid Plaques of Alzheimer's Disease , 1996, Journal of neuropathology and experimental neurology.
[30] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[31] Douglas Walker,et al. Inflammation and Alzheimer's disease pathogenesis , 1996, Neurobiology of Aging.
[32] F. Maxfield,et al. Slow Degradation of Aggregates of the Alzheimer’s Disease Amyloid β-Protein by Microglial Cells* , 1997, The Journal of Biological Chemistry.
[33] L. Mucke,et al. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease , 1997, Nature.
[34] B. Juurlink. Response of Glial Cells to Ischemia: Roles of Reactive Oxygen Species and Glutathione , 1997, Neuroscience & Biobehavioral Reviews.
[35] D. Walker,et al. Expression of presenilin-1 and -2 mRNAs in rat and Alzheimer's disease brains , 1997, Brain Research.
[36] L. Lue,et al. Molecular and Cellular Characterization of the Membrane Attack Complex, C5b-9, in Alzheimer’s Disease , 1997, Neurobiology of Aging.
[37] T. Johns,et al. Binding of complement component Clq to myelin oligodendrocyte glycoprotein: A novel mechanism for regulating CNS inflammation , 1997 .
[38] J. Loike,et al. Microglia, Scavenger Receptors, and the Pathogenesis of Alzheimer’s Disease , 1998, Neurobiology of Aging.
[39] Pier Paolo Pandolfi,et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies , 1998, Nature Genetics.
[40] A. Hoes,et al. NSAIDs and incident Alzheimer’s disease. the Rotterdam study , 1998, Neurobiology of Aging.
[41] E. Kokmen,et al. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. , 1998, Mayo Clinic proceedings.
[42] T. Johns,et al. Binding of complement component C1q to myelin oligodendrocyte glycoprotein: A novel mechanism for regulating CNS inflammation , 1998, Journal of Neuroimmunology.
[43] N. Delanty,et al. Risk of Alzheimer's disease and duration of NSAID use , 1998, Neurology.
[44] M. Carroll,et al. The role of complement and complement receptors in induction and regulation of immunity. , 1998, Annual review of immunology.
[45] S. Paul,et al. The NF-κB/Rel family of proteins mediates Aβ-induced neurotoxicity and glial activation , 1998 .
[46] S. Paul,et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[47] M. Mattson,et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. , 1999, Science.
[48] P. Gasque,et al. Differential expression of individual complement regulators in the brain and choroid plexus. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[49] P. Mcgeer,et al. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs , 1999, Brain Research.
[50] A. Tenner. Membrane receptors for soluble defense collagens. , 1999, Current opinion in immunology.
[51] P. Mcgeer,et al. Inflammation of the brain in Alzheimer's disease: implications for therapy , 1999, Journal of leukocyte biology.
[52] C. Plata-salamán,et al. Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.
[53] H J Koch,et al. A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.
[54] M. Emmerling,et al. The role of complement in Alzheimer's disease pathology. , 2000, Biochimica et biophysica acta.
[55] P. Mcgeer. Cyclo-Oxygenase-2 Inhibitors , 2000, Drugs & aging.
[56] M. Norton,et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists , 2000, Neurology.
[57] P. Taylor,et al. A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo , 2000, The Journal of experimental medicine.
[58] Rena Li,et al. Deficiency of Complement Defense Protein CD59 May Contribute to Neurodegeneration in Alzheimer's Disease , 2000, The Journal of Neuroscience.
[59] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[60] W. Griffin,et al. Overexpression of the Neuritotrophic Cytokine S100β Precedes the Appearance of Neuritic β‐Amyloid Plaques in APPV717F Mice , 2000 .
[61] S. Paul,et al. Overexpression of the neuritotrophic cytokine S100beta precedes the appearance of neuritic beta-amyloid plaques in APPV717F mice. , 2000, Journal of neurochemistry.
[62] L. Waite,et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. , 2000, Archives of neurology.
[63] P. Gasque,et al. Complement components of the innate immune system in health and disease in the CNS. , 2000, Immunopharmacology.
[64] Roger N Gunn,et al. In-vivo measurement of activated microglia in dementia , 2001, The Lancet.
[65] L. Mucke,et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice , 2001, Nature Medicine.
[66] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.
[67] M. Goldberg,et al. Amyloid-β Peptides Are Cytotoxic to Oligodendrocytes , 2001, The Journal of Neuroscience.
[68] Virginia M. Y. Lee,et al. Complement activation by neurofibrillary tangles in Alzheimer's disease , 2001, Neuroscience Letters.
[69] H. Hampel,et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro , 2001, Glia.
[70] D. Wilcock,et al. Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice , 2001, Neurobiology of Aging.
[71] D. Birmingham,et al. CR1 and CR1‐like: the primate immune adherence receptors , 2001, Immunological reviews.
[72] P. Worley,et al. Age-Dependent Cognitive Deficits and Neuronal Apoptosis in Cyclooxygenase-2 Transgenic Mice , 2001, The Journal of Neuroscience.
[73] L. Lue,et al. Modeling microglial activation in Alzheimer’s disease with human postmortem microglial cultures , 2001, Neurobiology of Aging.
[74] L. Lue,et al. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia , 2001, Neurobiology of Aging.
[75] E. Connolly,et al. The Role of the Complement Cascade in Ischemia/Reperfusion Injury: Implications for Neuroprotection , 2001, Molecular medicine.
[76] John D Lambris,et al. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity , 2001, Immunological reviews.
[77] David J. Cummins,et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[78] P. Rezaie,et al. MESOGLIA & MICROGLIA – A Historical Review of the Concept of Mononuclear Phagocytes Within the Central Nervous System , 2002, Journal of the history of the neurosciences.
[79] J. Berman,et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. , 2002, The American journal of pathology.
[80] Tony Wyss-Coray,et al. Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.
[81] C. Janeway,et al. Innate immune recognition. , 2002, Annual review of immunology.
[82] C. Wolfson,et al. A Case-Control Analysis of Nonsteroidal Anti-Inflammatory Drugs and Alzheimer’s Disease: Are They Protective? , 2002, Neuroepidemiology.
[83] D. Miller,et al. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[84] P. Zandi,et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study , 2002, Neurology.
[85] G. Garden. Microglia in human immunodeficiency virus‐associated neurodegeneration , 2002, Glia.
[86] John D Lambris,et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[87] J. Julien,et al. Innate immunity: the missing link in neuroprotection and neurodegeneration? , 2002, Nature Reviews Neuroscience.
[88] D. Basso,et al. The Neuropathological and Behavioral Consequences of Intraspinal Microglial/Macrophage Activation , 2002, Journal of neuropathology and experimental neurology.
[89] B. Winblad,et al. Up-regulation of the inflammatory cytokines IFN-γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice , 2002, Journal of Neuroimmunology.
[90] R. Hébert,et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. , 2002, American journal of epidemiology.
[91] D. Teplow,et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. , 2002, Gene expression.
[92] K. Moore,et al. CD36 Mediates the Innate Host Response to β-Amyloid , 2003, The Journal of experimental medicine.
[93] T. Wyss-Coray,et al. Adult mouse astrocytes degrade amyloid-β in vitro and in situ , 2003, Nature Medicine.
[94] J. Ryu,et al. Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. , 2003, Neuroreport.
[95] C. Brosnan,et al. Cytokines: Powerful Regulators of Glial Cell Activation , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[96] K. Davis,et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.
[97] J. Ting,et al. Functional Genomic Analysis of Remyelination Reveals Importance of Inflammation in Oligodendrocyte Regeneration , 2003, The Journal of Neuroscience.
[98] Pamela L. Follett,et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[99] G. Mcclearn,et al. Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged ≥80 years , 2003, European Journal of Clinical Pharmacology.
[100] P. Mcgeer,et al. Expression of complement messenger RNAs and proteins by human oligodendroglial cells , 2003, Glia.
[101] V. Perry,et al. Systemic infection, interleukin 1β, and cognitive decline in Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.
[102] M. D'Andrea. Evidence linking neuronal cell death to autoimmunity in Alzheimer’s disease , 2003, Brain Research.
[103] M. D'Andrea,et al. Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains , 2003, Brain Research.
[104] Andrea Russo,et al. Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[105] A. Iwasaki,et al. Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.
[106] C. Kawas,et al. Neuronal localization of C1q in preclinical Alzheimer's disease , 2004, Neurobiology of Disease.
[107] P. Mcgeer,et al. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease , 2004, Acta Neuropathologica.
[108] Rena Li,et al. CCAAT/enhancer binding protein δ (C/EBPδ) expression and elevation in Alzheimer’s disease , 2004, Neurobiology of Aging.
[109] Xi Chen,et al. RAGE potentiates Aβ‐induced perturbation of neuronal function in transgenic mice , 2004, The EMBO journal.
[110] S. Paul,et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.
[111] T. Town,et al. Neuronal expression of CD22: Novel mechanism for inhibiting microglial proinflammatory cytokine production , 2004, Glia.
[112] W. Markesbery,et al. Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[113] J. Julien,et al. Exacerbation of Motor Neuron Disease by Chronic Stimulation of Innate Immunity in a Mouse Model of Amyotrophic Lateral Sclerosis , 2004, The Journal of Neuroscience.
[114] Jun Zhou,et al. Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease , 2004, The Journal of Neuroscience.
[115] C. Lines,et al. Rofecoxib , 2004, Neurology.
[116] Xianlin Han,et al. Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase–ceramide pathway , 2004, The Journal of Cell Biology.
[117] P. Mcgeer,et al. Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs , 2004, Journal of Neuroinflammation.
[118] J. Mitchell,et al. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[119] P. Eikelenboom,et al. Immunoglobulins and complement factors in senile plaques , 1982, Acta Neuropathologica.
[120] Polly Matzinger,et al. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.
[121] Rena Li,et al. CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease. , 2004, Neurobiology of aging.
[122] P. Gasque. Complement: a unique innate immune sensor for danger signals. , 2004, Molecular immunology.
[123] M. Duchen,et al. β-Amyloid Peptides Induce Mitochondrial Dysfunction and Oxidative Stress in Astrocytes and Death of Neurons through Activation of NADPH Oxidase , 2004, The Journal of Neuroscience.
[124] B. Winblad,et al. Aspirin, NSAIDs, Risk of Dementia, and Influence of the Apolipoprotein E Epsilon 4 Allele in an Elderly Population , 2004, Neuroepidemiology.
[125] K. Ishii,et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[126] Jill A. White,et al. Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation , 2005, Neurobiology of Disease.
[127] L. Thal,et al. A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment , 2005, Neuropsychopharmacology.
[128] W. Gan,et al. ATP mediates rapid microglial response to local brain injury in vivo , 2005, Nature Neuroscience.
[129] Pritam Das,et al. Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production , 2005, Nature Medicine.
[130] S. Gordon,et al. Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.
[131] H. Neumann,et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. , 2005, Brain : a journal of neurology.
[132] K. Krause,et al. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases , 2005, Brain Research Reviews.
[133] R. von Bernhardi,et al. Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. , 2005, Biological research.
[134] E. Blalock,et al. Calcineurin Triggers Reactive/Inflammatory Processes in Astrocytes and Is Upregulated in Aging and Alzheimer's Models , 2005, The Journal of Neuroscience.
[135] F. Helmchen,et al. Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo , 2005, Science.
[136] A. Stromberg,et al. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: Statistical reliability and functional correlation , 2005, Ageing Research Reviews.
[137] W. Blakemore,et al. Inflammation stimulates remyelination in areas of chronic demyelination. , 2005, Brain : a journal of neurology.
[138] V. Perry,et al. Central and Systemic Endotoxin Challenges Exacerbate the Local Inflammatory Response and Increase Neuronal Death during Chronic Neurodegeneration , 2005, The Journal of Neuroscience.
[139] L. Lue,et al. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases , 2005, Journal of neuroscience research.
[140] L. V. Van Eldik,et al. Enhanced susceptibility of S‐100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human β‐amyloid , 2005, Glia.
[141] Z. Janka,et al. Gene expression profile analysis of lymphocytes from Alzheimer's patients , 2005, Psychiatric genetics.
[142] James L. Buescher,et al. Overexpression of monocyte chemotactic protein-1/ CCL2 in β-amyloid precursor protein transgenic mice show accelerated diffuse β-amyloid deposition , 2005 .
[143] T. Montine,et al. Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.
[144] P. Moynagh. The interleukin‐1 signalling pathway in astrocytes: a key contributor to inflammation in the brain , 2005, Journal of anatomy.
[145] Ling Li,et al. Role of toll-like receptor signalling in Abeta uptake and clearance. , 2006, Brain : a journal of neurology.
[146] A. Savonenko,et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer’s disease in a sex-dimorphic pattern , 2006, Neuroscience.
[147] Chao Zhao,et al. Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells , 2006, Glia.
[148] S. Lovestone,et al. Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.
[149] Rena Li,et al. Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes , 2006, Neurobiology of Aging.
[150] B. Martin,et al. Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) , 2006, PLoS clinical trials.
[151] D. Holtzman,et al. Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism , 2006, The Journal of Neuroscience.
[152] L. Mucke,et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. , 2006, The Journal of clinical investigation.
[153] B. Botterman,et al. Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease , 2006, The Journal of Neuroscience.
[154] E. Sigurdsson,et al. Plaque-Associated Overexpression of Insulin-Degrading Enzyme in the Cerebral Cortex of Aged Transgenic Tg2576 Mice With Alzheimer Pathology , 2006, Journal of neuropathology and experimental neurology.
[155] R. Ransohoff,et al. The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.
[156] Tony Wyss-Coray,et al. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.
[157] E. Sheta,et al. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases , 2006, Expert review of proteomics.
[158] J. Rogers,et al. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. , 2006, Journal of Alzheimer's disease : JAD.
[159] Hyman M. Schipper,et al. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray , 2007, Neurobiology of Aging.
[160] Michael M. Halassa,et al. Synaptic Islands Defined by the Territory of a Single Astrocyte , 2007, The Journal of Neuroscience.
[161] L. McCullough,et al. Function of COX-2 and Prostaglandins in Neurological Disease , 2007, Journal of Molecular Neuroscience.
[162] X. Chen,et al. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. , 2007, Current molecular medicine.
[163] A. Bessis,et al. Microglial control of neuronal death and synaptic properties , 2007, Glia.
[164] D. Blacker,et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.
[165] B. Winblad,et al. Decreased Fractalkine and Increased IP-10 Expression in Aged Brain of APPswe Transgenic Mice , 2008, Neurochemical Research.
[166] R. Green,et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial , 2007, Neurology.
[167] John D. Lambris,et al. The Classical Complement Cascade Mediates CNS Synapse Elimination , 2007, Cell.
[168] W. Robberecht,et al. Microglia in amyotrophic lateral sclerosis. , 2007, Acta neurologica Belgica.
[169] P. Rezaie,et al. The origin and cell lineage of microglia—New concepts , 2007, Brain Research Reviews.
[170] S. Lockett,et al. Induction of the Formyl Peptide Receptor 2 in Microglia by IFN-γ and Synergy with CD40 Ligand12 , 2007, The Journal of Immunology.
[171] G. Martino,et al. Multifaceted aspects of inflammation in multiple sclerosis: The role of microglia , 2007, Journal of Neuroimmunology.
[172] P. Zandi,et al. NSAIDs for the chemoprevention of Alzheimer's disease. , 2007, Sub-cellular biochemistry.
[173] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[174] M. O’Banion,et al. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. , 2007, The Journal of clinical investigation.
[175] Rajagopal N. Aravalli,et al. Toll-like Receptors in Defense and Damage of the Central Nervous System , 2007, Journal of Neuroimmune Pharmacology.
[176] R. Ransohoff. The MHP36 line of murine neural stem cells expresses functional CXCR1 chemokine receptors that initiate chemotaxis in vitro. , 2007, Journal of neuroimmunology.
[177] D. Menon,et al. The MHP36 line of murine neural stem cells expresses functional CXCR1 chemokine receptors that initiate chemotaxis in vitro , 2007, Journal of Neuroimmunology.
[178] J. Rogers,et al. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? , 2007, International review of neurobiology.
[179] Holger Heine,et al. Role of the Toll-Like Receptor 4 in Neuroinflammation in Alzheimer’s Disease , 2007, Cellular Physiology and Biochemistry.
[180] C. Geula,et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.
[181] O. Hurtado,et al. Toll-Like Receptor 4 Is Involved in Brain Damage and Inflammation After Experimental Stroke , 2007, Circulation.
[182] F. Maxfield,et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. , 2007, Molecular biology of the cell.
[183] J. Ringman,et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin , 2007, Proceedings of the National Academy of Sciences.
[184] Rena Li,et al. Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice , 2007, The Journal of Cell Biology.
[185] S. Lockett,et al. Induction of the formyl peptide receptor 2 in microglia by IFN-gamma and synergy with CD40 ligand. , 2007, Journal of immunology.
[186] C. Ferrari,et al. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease , 2008, Brain : a journal of neurology.
[187] Jing Zhang,et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.
[188] H. Brodaty,et al. Faculty Opinions recommendation of NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. , 2008 .
[189] N. Grigoriadis,et al. Increased expression of the γ‐secretase components presenilin‐1 and nicastrin in activated astrocytes and microglia following traumatic brain injury , 2008, Glia.
[190] A. Luster,et al. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. , 2008, Trends in pharmacological sciences.
[191] Makoto Sawada,et al. Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies , 2008, The Journal of Neuroscience.
[192] G. Landreth,et al. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. , 2008, CNS drugs.
[193] F. Haiss,et al. Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance , 2008, The Journal of Neuroscience.
[194] F. Maxfield,et al. Degradation of fibrillar forms of Alzheimer's amyloid β-peptide by macrophages , 2008, Neurobiology of Aging.
[195] Martin Rossor,et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study , 2008, Neurobiology of Disease.
[196] V. Echeverria,et al. Transcription factor Sp1 dysregulation in Alzheimer's disease , 2008, Journal of neuroscience research.
[197] Hong-Duck Kim,et al. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease , 2008, Journal of Neuroinflammation.
[198] V. Perry,et al. Systemic inflammation switches the inflammatory cytokine profile in CNS Wallerian degeneration , 2008, Neurobiology of Disease.
[199] D. Holtzman,et al. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.
[200] C. Bogdan. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example , 2008, Cellular microbiology.
[201] K. L. Richard,et al. Toll-Like Receptor 2 Acts as a Natural Innate Immune Receptor to Clear Amyloid β1–42 and Delay the Cognitive Decline in a Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.
[202] T. Pufe,et al. Involvement of formyl-peptide-receptor-like-1 and phospholipase D in the internalization and signal transduction of amyloid beta 1-42 in glial cells , 2008, Neuroscience.
[203] D. Holtzman,et al. Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-Aβ Antibody Administration in PDAPP Mice , 2008, The Journal of Neuroscience.
[204] G. Landreth,et al. The Role of Peroxisome Proliferator-Activated Receptor-γ PPARγ) in Alzheimer’s Disease , 2012 .
[205] D. Bennett,et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology , 2008, Neurology.
[206] C. Lemere,et al. Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice , 2008, The Journal of Neuroscience.
[207] Donald R. Miller,et al. Protective effects of NSAIDs on the development of Alzheimer disease , 2008, Neurology.
[208] M. Goldberg,et al. Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration , 2008, The Journal of Neuroscience.
[209] Jun Tan,et al. Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology , 2008, Nature Medicine.
[210] C. Cao,et al. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice , 2009, Neuroscience.
[211] M. Sofroniew,et al. Astrocytes: biology and pathology , 2009, Acta Neuropathologica.
[212] Monique Breteler,et al. Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels , 2009, Annals of the New York Academy of Sciences.
[213] H. Abdul,et al. Cognitive Decline in Alzheimer's Disease Is Associated with Selective Changes in Calcineurin/NFAT Signaling , 2009, The Journal of Neuroscience.
[214] R. Nelson,et al. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. , 2009, Current opinion in investigational drugs.
[215] C. Combs. Inflammation and Microglia Actions in Alzheimer’s Disease , 2009, Journal of Neuroimmune Pharmacology.
[216] J. Nabekura,et al. Resting Microglia Directly Monitor the Functional State of Synapses In Vivo and Determine the Fate of Ischemic Terminals , 2009, The Journal of Neuroscience.
[217] Julie Price,et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. , 2009, Archives of neurology.
[218] G. van Dijk,et al. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. , 2009, Journal of Alzheimer's disease : JAD.
[219] P. Magistretti,et al. The role of astroglia in neuroprotection , 2009, Dialogues in clinical neuroscience.
[220] P. Bosco,et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.
[221] G. Landreth,et al. Toll-like receptors in Alzheimer's disease. , 2009, Current topics in microbiology and immunology.
[222] M. Mattson,et al. Involvement of Fc Receptors in Disorders of the Central Nervous System , 2010, NeuroMolecular Medicine.
[223] A. Dolga,et al. Inflammation and NF-κB in Alzheimer’s Disease and Diabetes , 2009 .
[224] Robert C Green,et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.
[225] S. Haneuse,et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort , 2009, Neurology.
[226] J. Calderó,et al. Development of microglia in the chick embryo spinal cord: Implications in the regulation of motoneuronal survival and death , 2009, Journal of neuroscience research.
[227] W. Seaman,et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia , 2009, Journal of neurochemistry.
[228] Yan Wang,et al. Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice , 2009, The Journal of Neuroscience.
[229] Vahram Haroutunian,et al. Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals , 2009, PloS one.
[230] C. Colton. Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain , 2009, Journal of Neuroimmune Pharmacology.
[231] C. Heizmann,et al. RAGE Does Not Affect Amyloid Pathology in Transgenic ArcAβ Mice , 2010, Neurodegenerative Diseases.
[232] W. Streit,et al. Life and Death of Microglia , 2009, Journal of Neuroimmune Pharmacology.
[233] Jose Julio Rodriguez,et al. Astroglia in dementia and Alzheimer's disease , 2009, Cell Death and Differentiation.
[234] G. Landreth,et al. CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation , 2009, The Journal of Neuroscience.
[235] A. Kirkwood,et al. Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor , 2009, Experimental Neurology.
[236] P. Pasqualetti,et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease , 2009, Aging clinical and experimental research.
[237] L. Lue,et al. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: A potential mechanism leading to chronic inflammation , 2009, Experimental Neurology.
[238] J. Relton,et al. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. , 2008, Brain : a journal of neurology.
[239] T. Montine,et al. The Prostaglandin E2 E-Prostanoid 4 Receptor Exerts Anti-Inflammatory Effects in Brain Innate Immunity , 2010, The Journal of Immunology.
[240] G. Landreth,et al. Microglia and inflammation in Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.
[241] G. Halliday,et al. Focal demyelination in Alzheimer’s disease and transgenic mouse models , 2010, Acta Neuropathologica.
[242] Brent D. Cameron,et al. Inflammation, microglia, and alzheimer's disease , 2010, Neurobiology of Disease.
[243] K. Lunetta,et al. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. , 2010, Archives of neurology.
[244] Susan M Resnick,et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.
[245] G. Landreth,et al. The role of microglia in amyloid clearance from the AD brain , 2010, Journal of Neural Transmission.
[246] Christopher L. MacDonald,et al. Amyloid β-peptide directly induces spontaneous calcium transients, delayed intercellular calcium waves and gliosis in rat cortical astrocytes , 2009, ASN neuro.
[247] A. Tenner,et al. C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production , 2010, Journal of neurochemistry.
[248] D. Dickson,et al. Massive gliosis induced by interleukin‐6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[249] S. Nam,et al. Inflammation and Alzheimer’s disease , 2010, Archives of pharmacal research.
[250] Murray Grossman,et al. Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment , 2010, Acta Neuropathologica.
[251] P. Zandi,et al. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. , 2010, CNS & neurological disorders drug targets.
[252] S. C.A.,et al. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. , 2010 .
[253] Murray Grossman,et al. Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease , 2010, Acta Neuropathologica.
[254] C. Colton,et al. Assessing activation states in microglia. , 2010, CNS & neurological disorders drug targets.
[255] K. Nakashima,et al. [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.
[256] Thomas W. Mühleisen,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.
[257] A. Lbert,et al. Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .